- ABSTRACT.
- INTRODUCTION
- MATERIALS AND METHODS
- General information.
- Inclusion criteria.
- Exclusion criteria.
- Antituberculosis treatment plan.
- Definition of DILI.
- Specific laboratory index threshold for diagnosis of diabetes.
- Patient follow-up arrangements.
- Biochemical analyzer detection.
- ELISA detection.
- Computed tomography scanning analysis.
- Incidence of adverse reactions.
- STATISTICAL ANALYSES
- RESULTS
- DISCUSSION
- REFERENCES
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Kumar Y, Koul A, Singla R, Ijaz MF, 2023. Artificial intelligence in disease diagnosis: A systematic literature review, synthesizing framework and future research agenda. J Ambient Intell Humaniz Comput 14: 8459–8486.
-
2.
Gupta P, et al., 2022. Indian Academy of Pediatrics revised (2021) guidelines on prevention and treatment of vitamin D deficiency and rickets. Indian Pediatr 59: 142–158.
-
3.
Al-Shahrani MS, Hakami MI, Younis MA, Fan HA, Jeraiby MA, Alraey Y, 2021. Prevalence of primary anti-tuberculosis drug resistance at the tertiary center in Saudi Arabia and associated risk factors. Saudi Med J 42: 728–734.
-
4.
Lu P, Zhang Y, Liu Q, Ding X, Kong W, Zhu L, Lu W, 2021. Association of BMI, diabetes, and risk of tuberculosis: A population-based prospective cohort. Int J Infect Dis 109: 168–173.
-
5.
Chen Z, Liu Q, Song R, Zhang W, Wang T, Lian Z, Sun X, Liu Y, 2021. The association of glycemic level and prevalence of tuberculosis: A meta-analysis. BMC Endocr Disord 21: 123.
-
6.
Sadeghi MB, Nakhaee A, Saravani R, 2021. Significant association of LXRβ (NR1H2) polymorphisms (rs28514894, rs2303044) with type 2 diabetes mellitus and laboratory characteristics. J Diabetes Metab Disord 20: 261–270.
-
7.
Hesse R, van der Westhuizen DJ, George JA, 2021. COVID-19-related laboratory analyte changes and the relationship between SARS-CoV-2 and HIV, TB, and HbA1c in South Africa. Adv Exp Med Biol 1321: 183–197.
-
8.
Böhler M, van den Berg EH, Almanza MCT, Connelly MA, Bakker SJL, de Meijer VE, Dullaart RPF, Blokzijl H, 2022. Branched chain amino acids are associated with metabolic complications in liver transplant recipients. Clin Biochem 102: 26–33.
-
9.
Kang W, et al., 2021. The prevalence and risks of major comorbidities among inpatients with pulmonary tuberculosis in China from a gender and age perspective: A large-scale multicenter observational study. Eur J Clin Microbiol Infect Dis 40: 787–800.
-
10.
Iqbal P, Soliman A, De Sanctis V, Yassin MA, 2021. Association of tuberculosis in patients with chronic myeloid leukemia: A treatment proposal based on literature review. Expert Rev Hematol 14: 211–217.
-
11.
Gandotra A, Mehtani R, Premkumar M, Duseja A, De A, Mallik N, Durgadevi S, Das A, Kalra N, 2022. Invasive pulmonary aspergillosis and tuberculosis complicated by hemophagocytic lymphohistiocytosis—Sequelae of COVID-19 in a liver transplant recipient. J Clin Exp Hepatol 12: 1007–1011.
-
12.
Juárez SP, Cederström A, Aradhya S, 2023. Differences in hospitalizations associated with severe COVID-19 disease among foreign- and Swedish-born. Eur J Public Health 33: 522–527.
-
13.
López-Torres MO, Marquina-Castillo B, 2021. 16α-Bromoepiandrosterone as a new candidate for experimental diabetes-tuberculosis co-morbidity treatment. Clin Exp Immunol 205: 232–245.
-
14.
Nejatollahi SMR, Nazari M, 2023. Reoperation etiologies in the initial hospital stay after liver transplantation: A single-center study from Iran. Korean J Transplant 37: 103–108.
-
15.
Lommatzsch M, et al., 2022. Risk assessment for patients with chronic respiratory conditions in the context of the SARS-CoV-2 pandemic statement of the German Respiratory Society with the support of the German Association of Chest Physicians. Respiration 101: 307–320.
-
16.
Spearman CW, et al., 2021. Health-care provision and policy for non-alcoholic fatty liver disease in sub-Saharan Africa. Lancet Gastroenterol Hepatol 6: 1047–1056.
-
17.
Wang N, et al., 2022. Relevance of gene polymorphisms of NAT2 and NR1I2 to anti-tuberculosis drug-induced hepatotoxicity. Xenobiotica 52: 520–526.
-
18.
Han X, Liu X, Zhong F, Wang Y, Guan H, Zhang Q, 2021. Comparison of efficacy and safety of complementary and alternative therapies for coronary heart disease complicated with anxiety or depression disorder: A protocol for Bayesian network meta-analysis. Medicine (Baltimore) 100: e25084.
-
19.
Sharma A, Bhardwaj A, Mathur RP, 2021. Incidence and causes of late hospital readmissions after living donor renal transplant: A retrospective study. Exp Clin Transplant 19: 420–424.
-
20.
Jeyakumar SM, Vajreswari A, 2021. Pharmaconutrition strategy to resolve SARS-CoV-2-induced inflammatory cytokine storm in non-alcoholic fatty liver disease: Omega-3 long-chain polyunsaturated fatty acids. World J Clin Cases 9: 9333–9349.
-
21.
Munyemana JB, Mukanoheli E, Nsabimana T, Niringiyumukiza JD, 2021. HCV seroprevalence among HIV patients and associated comorbidities at one primary health facility in Rwanda. Am J Trop Med Hyg 104: 1747–1750.
-
22.
Smvk P, Kommu S, Yadav D, Kondeti S, Kalashikam RR, Natarajan S, 2022. Effect of different dietary fats on inflammation and glucose intolerance in high fructose and high fat fed experimental animals. Horm Mol Biol Clin Investig 43: 307–314.
-
23.
Tanoglu A, et al., 2023. Clinicopathological profile of peritoneal tuberculosis and a new scoring model for predicting mortality: An international ID-IRI study. Eur J Clin Microbiol Infect Dis 42: 981–992.
-
24.
Law MG, et al., 2003. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int J Epidemiol 32: 717–724.
-
25.
Rau C, et al., 2023. Treatment of infants and children with SARS-CoV-2 monoclonal antibodies: A European case series. Pediatr Infect Dis J 42: 125–129.
-
26.
Mohamed Noor NF, Salleh MZ, 2022. NAT2 polymorphism and clinical factors that increase antituberculosis drug-induced hepatotoxicity. Pharmacogenomics 23: 531–541.
-
27.
Hoti KD, et al., 2022. Biliary cystadenoma: Case report with MRI findings and surgical confirmation. Radiol Case Rep 17: 3974–3978.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 829 | 829 | 760 |
| Full Text Views | 12 | 12 | 5 |
| PDF Downloads | 18 | 18 | 6 |
Key Factors Influencing Liver Function Injury in Elderly Patients with Newly Diagnosed Pulmonary Tuberculosis Complicated by Diabetes after Antituberculosis Treatment
Liangliang Ma
mlldr2022@sina.com
Liangliang Ma
Department of Infective Diseases, Beijing Geriatric Hospital, Beijing, China;
Search for other papers by Liangliang Ma in
Current site
Google Scholar
PubMed
Search for other papers by Liangliang Ma in
Current site
Google Scholar
PubMed
Henghua Fan
Henghua Fan
Orthopedics Department, The Fourth People’s Hospital of Shenzhen, Shenzhen, China
Search for other papers by Henghua Fan in
Current site
Google Scholar
PubMed
Search for other papers by Henghua Fan in
Current site
Google Scholar
PubMed
ABSTRACT.
This study addressed the factors influencing liver injury in elderly patients newly diagnosed with pulmonary tuberculosis and diabetes after antituberculosis treatment. From January 2021 to June 2023, 218 elderly patients with early treatment of pulmonary tuberculosis (N = 218) combined with diabetes (N = 218) were collected as research subjects. All patients were treated with the same antituberculosis treatment regimen and were divided into a nonhepatotoxicity group (N = 92) and a hepatotoxicity group (N = 126) according to whether drug-induced liver injury occurred within 3 months after taking tuberculosis drugs. The levels of alanine aminotransferase and aspartate aminotransferase, total bilirubin, direct bilirubin, indirect bilirubin, albumin, lipoprotein(a), prothrombin time, and hemoglobin A1c (HbA1c) were detected by biochemical analyzer. The extent of pulmonary tuberculosis lesions was examined by computed tomography imaging. Influencing factors of antituberculosis drug-induced liver injury were analyzed by logistic multivariate analysis. The hepatotoxicity group exhibited a higher average age than the nonhepatotoxicity group (P <0.05). Additionally, there was a greater prevalence of patients with a history of alcohol consumption in the hepatotoxicity group than in the nonhepatotoxicity group (P <0.05). And the hepatotoxicity group showed a greater extent of tuberculosis lesions (P <0.05). Logistic multivariate analysis identified advanced age, body mass index of <18.5, lesion range of ≥2 lung lobes, history of alcohol consumption, and HbA1c of ≥8% as relevant factors associated with liver function impairment in older adults patients undergoing early treatment of pulmonary tuberculosis combined with diabetes after antituberculosis therapy. These findings underscore the importance of monitoring and addressing these factors during antituberculosis therapy in the elderly population to mitigate the risk of liver function impairment.
Author Notes
Disclosures: The study protocol was approved by the Ethics Committee of Beijing Geriatric Hospital. Informed consent was obtained from all the study subjects before enrollment.
Authors’ contributions: L. Ma contributed to the conception and design of the study, manuscript drafting, and project supervision. H. Fan participated in the clinical practice, including diagnosis, treatment, consultation, and follow-up of patients, and contributed to data collection and analysis. All authors revised and approved the final version of the manuscript.
Data availability: The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.
Current contact information: Liangliang Ma, Department of Infective Diseases, Beijing Geriatric Hospital, Beijing, China, E-mail: mlldr2022@sina.com. Henghua Fan, Orthopedics Department, The Fourth People’s Hospital of Shenzhen, Shenzhen, China, E-mail: rfwv92@163.com.
- ABSTRACT.
- INTRODUCTION
- MATERIALS AND METHODS
- General information.
- Inclusion criteria.
- Exclusion criteria.
- Antituberculosis treatment plan.
- Definition of DILI.
- Specific laboratory index threshold for diagnosis of diabetes.
- Patient follow-up arrangements.
- Biochemical analyzer detection.
- ELISA detection.
- Computed tomography scanning analysis.
- Incidence of adverse reactions.
- STATISTICAL ANALYSES
- RESULTS
- DISCUSSION
- REFERENCES
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Kumar Y, Koul A, Singla R, Ijaz MF, 2023. Artificial intelligence in disease diagnosis: A systematic literature review, synthesizing framework and future research agenda. J Ambient Intell Humaniz Comput 14: 8459–8486.
-
2.
Gupta P, et al., 2022. Indian Academy of Pediatrics revised (2021) guidelines on prevention and treatment of vitamin D deficiency and rickets. Indian Pediatr 59: 142–158.
-
3.
Al-Shahrani MS, Hakami MI, Younis MA, Fan HA, Jeraiby MA, Alraey Y, 2021. Prevalence of primary anti-tuberculosis drug resistance at the tertiary center in Saudi Arabia and associated risk factors. Saudi Med J 42: 728–734.
-
4.
Lu P, Zhang Y, Liu Q, Ding X, Kong W, Zhu L, Lu W, 2021. Association of BMI, diabetes, and risk of tuberculosis: A population-based prospective cohort. Int J Infect Dis 109: 168–173.
-
5.
Chen Z, Liu Q, Song R, Zhang W, Wang T, Lian Z, Sun X, Liu Y, 2021. The association of glycemic level and prevalence of tuberculosis: A meta-analysis. BMC Endocr Disord 21: 123.
-
6.
Sadeghi MB, Nakhaee A, Saravani R, 2021. Significant association of LXRβ (NR1H2) polymorphisms (rs28514894, rs2303044) with type 2 diabetes mellitus and laboratory characteristics. J Diabetes Metab Disord 20: 261–270.
-
7.
Hesse R, van der Westhuizen DJ, George JA, 2021. COVID-19-related laboratory analyte changes and the relationship between SARS-CoV-2 and HIV, TB, and HbA1c in South Africa. Adv Exp Med Biol 1321: 183–197.
-
8.
Böhler M, van den Berg EH, Almanza MCT, Connelly MA, Bakker SJL, de Meijer VE, Dullaart RPF, Blokzijl H, 2022. Branched chain amino acids are associated with metabolic complications in liver transplant recipients. Clin Biochem 102: 26–33.
-
9.
Kang W, et al., 2021. The prevalence and risks of major comorbidities among inpatients with pulmonary tuberculosis in China from a gender and age perspective: A large-scale multicenter observational study. Eur J Clin Microbiol Infect Dis 40: 787–800.
-
10.
Iqbal P, Soliman A, De Sanctis V, Yassin MA, 2021. Association of tuberculosis in patients with chronic myeloid leukemia: A treatment proposal based on literature review. Expert Rev Hematol 14: 211–217.
-
11.
Gandotra A, Mehtani R, Premkumar M, Duseja A, De A, Mallik N, Durgadevi S, Das A, Kalra N, 2022. Invasive pulmonary aspergillosis and tuberculosis complicated by hemophagocytic lymphohistiocytosis—Sequelae of COVID-19 in a liver transplant recipient. J Clin Exp Hepatol 12: 1007–1011.
-
12.
Juárez SP, Cederström A, Aradhya S, 2023. Differences in hospitalizations associated with severe COVID-19 disease among foreign- and Swedish-born. Eur J Public Health 33: 522–527.
-
13.
López-Torres MO, Marquina-Castillo B, 2021. 16α-Bromoepiandrosterone as a new candidate for experimental diabetes-tuberculosis co-morbidity treatment. Clin Exp Immunol 205: 232–245.
-
14.
Nejatollahi SMR, Nazari M, 2023. Reoperation etiologies in the initial hospital stay after liver transplantation: A single-center study from Iran. Korean J Transplant 37: 103–108.
-
15.
Lommatzsch M, et al., 2022. Risk assessment for patients with chronic respiratory conditions in the context of the SARS-CoV-2 pandemic statement of the German Respiratory Society with the support of the German Association of Chest Physicians. Respiration 101: 307–320.
-
16.
Spearman CW, et al., 2021. Health-care provision and policy for non-alcoholic fatty liver disease in sub-Saharan Africa. Lancet Gastroenterol Hepatol 6: 1047–1056.
-
17.
Wang N, et al., 2022. Relevance of gene polymorphisms of NAT2 and NR1I2 to anti-tuberculosis drug-induced hepatotoxicity. Xenobiotica 52: 520–526.
-
18.
Han X, Liu X, Zhong F, Wang Y, Guan H, Zhang Q, 2021. Comparison of efficacy and safety of complementary and alternative therapies for coronary heart disease complicated with anxiety or depression disorder: A protocol for Bayesian network meta-analysis. Medicine (Baltimore) 100: e25084.
-
19.
Sharma A, Bhardwaj A, Mathur RP, 2021. Incidence and causes of late hospital readmissions after living donor renal transplant: A retrospective study. Exp Clin Transplant 19: 420–424.
-
20.
Jeyakumar SM, Vajreswari A, 2021. Pharmaconutrition strategy to resolve SARS-CoV-2-induced inflammatory cytokine storm in non-alcoholic fatty liver disease: Omega-3 long-chain polyunsaturated fatty acids. World J Clin Cases 9: 9333–9349.
-
21.
Munyemana JB, Mukanoheli E, Nsabimana T, Niringiyumukiza JD, 2021. HCV seroprevalence among HIV patients and associated comorbidities at one primary health facility in Rwanda. Am J Trop Med Hyg 104: 1747–1750.
-
22.
Smvk P, Kommu S, Yadav D, Kondeti S, Kalashikam RR, Natarajan S, 2022. Effect of different dietary fats on inflammation and glucose intolerance in high fructose and high fat fed experimental animals. Horm Mol Biol Clin Investig 43: 307–314.
-
23.
Tanoglu A, et al., 2023. Clinicopathological profile of peritoneal tuberculosis and a new scoring model for predicting mortality: An international ID-IRI study. Eur J Clin Microbiol Infect Dis 42: 981–992.
-
24.
Law MG, et al., 2003. Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001. Int J Epidemiol 32: 717–724.
-
25.
Rau C, et al., 2023. Treatment of infants and children with SARS-CoV-2 monoclonal antibodies: A European case series. Pediatr Infect Dis J 42: 125–129.
-
26.
Mohamed Noor NF, Salleh MZ, 2022. NAT2 polymorphism and clinical factors that increase antituberculosis drug-induced hepatotoxicity. Pharmacogenomics 23: 531–541.
-
27.
Hoti KD, et al., 2022. Biliary cystadenoma: Case report with MRI findings and surgical confirmation. Radiol Case Rep 17: 3974–3978.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 829 | 829 | 760 |
| Full Text Views | 12 | 12 | 5 |
| PDF Downloads | 18 | 18 | 6 |